Ionis Pharmaceuticals (IONS) Retained Earnings (2009 - 2026)

Ionis Pharmaceuticals' Retained Earnings history runs 18 years deep, the most recent figure standing at -$2.8 billion for Q2 2026.

• In Q2 2026, Retained Earnings fell 24.86% year-over-year to -$2.8 billion; the TTM figure through Jun 2026 stood at -$2.8 billion (down 24.86% YoY), while the FY2025 annual figure was -$2.6 billion, down 16.95% from the prior year.
• Retained Earnings for Q2 2026 stood at -$2.8 billion, down from -$2.7 billion in the prior quarter.
• The five-year high for Retained Earnings was -$1.2 billion in Q1 2022, with the low at -$2.8 billion in Q2 2026.
• The 5-year median for Retained Earnings is -$2.0 billion (2024), against an average of -$2.0 billion.
• The sharpest annual moves came in 2022 and 2023: Retained Earnings climbed 0.53% in 2022, then declined 29.73% in 2023.
• Ionis Pharmaceuticals' Retained Earnings stood at -$1.4 billion in 2022, then decreased by 25.62% to -$1.8 billion in 2023, then dropped by 25.27% to -$2.2 billion in 2024, then dropped by 16.95% to -$2.6 billion in 2025, then retreated by 7.87% to -$2.8 billion in 2026.
• Business Quant data shows IONS's Retained Earnings at -$2.8 billion in Q2 2026, -$2.7 billion in Q1 2026, and -$2.6 billion in Q4 2025.